Ustekinumab is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
In two Phase III trials for moderate to severe psoriasis, the longest greater than 76 weeks, ustekinumab was safe and effective.


This video is targeted to blind users.

Attribution:
Article text available under CC-BY-SA
Creative Commons image source in video

свернуть